Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

Trends That Matter for Biosimilars

Posted by Matt Breese on Jun 22, 2017

In our weekly Trends that Matter series, we provide engaging infographics and recent news from healthcare influencers to highlight general trends affecting the pharmaceutical industry. This week's featured topic is the Supreme Court's recent Sandoz-Amgen decision in favor of biosimilar developers. 

This ruling will give patients earlier access to a wider variety of treatment options. According to Genetic Engineering & Biotechnology News, biosimilar developers will no longer need to wait an additional six months to introduce their treatments to market.

Read More

Topics: Industry Trends, Market Access

MMIT Reality Check on Hemophilia (Jun 2017)

Posted by Matt Breese on Jun 21, 2017

According to our recent payer coverage analysis for hemophilia treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

Perspectives on Medical Benefit Evolution

Posted by Matt Breese on Jun 21, 2017

Over time, medical benefits and restrictions have changed and expanded in the United States. Looking back at the historical timeline of healthcare policy can help provide context on the state of American healthcare as it exists today.

Before the 1930s, individuals were mainly responsible for covering their medical costs. In 1943, employers began to sponsor health insurance for the first time. According to JP Griffin Group, companies initially offered health benefits as a method to prevent inflation after WWII:

Read More

Topics: Market Access

MMIT Reality Check on G-CSF (Jun 2017)

Posted by Matt Breese on Jun 16, 2017

According to our recent payer coverage analysis for G-CSF treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

Note from the Editor: due to the importance of medical benefit for G-CSF, we've updated this reality check to include a snapshot of market access across medical benefit.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

Trends That Matter for Global Health

Posted by Matt Breese on Jun 15, 2017

In our weekly Trends that Matter series, we provide engaging infographics from healthcare influencers to highlight general trends affecting the pharmaceutical industry. This week's featured topic is the industry's contributions to global health.

Pharma organizations add value to global health causes through research projects, immunizations, medical access, and partnerships. In recent years, corporate social responsibility (CSR) has become increasingly important to pharma companies. In a 2015 Global Health Report, Hayley Droppert studied the relationship between corporate social responsibility and multinational pharmaceutical firms. 

Read More

Topics: Industry Trends

MMIT Reality Check on Heart Failure (Jun 2017)

Posted by Matt Breese on Jun 14, 2017

According to our recent payer coverage analysis for chronic heart failure treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

Perspectives on the Role of HCP Office Staff

Posted by Matt Breese on Jun 13, 2017

Pharmaceutical brand marketers win when prescribers are aware of their brand, understand its clinical value and can easily prescribe the product to patients. However, many prescribers are limiting facetime with pharma reps today. Some health practices have rules in place that prevent pharma reps from performing marketing activities in a clinical setting. In other cases, there's simply no spare time for clinicians to meet with reps due to high patient volumes. 

The ease of prescribing is usually directly related to a brand’s market access. In some situations, the physician’s office staff has the job of ensuring that treatment is delivered to the patient as quickly as possible. Office administrators often act as the gatekeeper between pharma reps and clinicians. For example, HCP office staff typically perform the busy work of fulfilling a prescription, calling-in to pharmacies, and pulling any necessary forms. In these situations, it’s valuable for pharma reps to deliver messages that can be passed along to staff. 

Read More

Topics: Market Access

Trends That Matter for Pharma's Economic Footprint

Posted by Matt Breese on Jun 8, 2017

In our weekly Trends that Matter series, we provide engaging infographics from healthcare influencers to highlight general trends affecting the pharmaceutical industry. This week's featured topic is the industry's economic footprint. Pharma adds a tremendous amount of value to the U.S. and global economies through job creation, medical research, drug development, immunizations, and health partnerships.

Having a strong pharma presence in a community helps support local businesses: According to the Pharmaceutical Research and Manufacturers of America (PhRMA):

"The industry helps support a vibrant scientific and economic ecosystem that is vital to the U.S. economy and our country’s competitiveness in the global market. Biopharmaceutical companies put down roots in communities across the country, helping to generate jobs across a whole range of sectors, from suppliers to retail to personal services."

Read More

Topics: Industry Trends

Perspectives on the Velocity of Payer Access Shifts

Posted by Matt Breese on Jun 7, 2017

Changes in market access occur at a variety of paces, depending on the disease area and other downstream drivers. Market events such as a new drug launch or a drug going off patent are good indicators that a wave of changes will arrive soon. For brand marketers, establishing a framework and cadence to track and react to specific market events is critical. This framework helps companies to stay ahead in their landscape and optimize emerging market opportunities.

Brand teams need to understand how often to monitor market access changes. This rate will vary depending on their class and their top priority payers and PBMs. Marketers should also consider historical formulary changes, analogs for similar products, and the contracting tactics used by competitive manufacturers. 

Read More

Topics: Industry Trends, Market Access

MMIT Reality Check on Dermatology: Acne (June 2017)

Posted by Matt Breese on Jun 2, 2017

According to our recent payer coverage analysis for dermatology-acne, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing